Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1563090 | 0.96 | POLB (0.45) | RAB9AKMT2ALMNAPOLBCXCR2 | |
| SCHEMBL17293485 | 0.91 | ALDH1A1 (0.40) | KMT2ALMNAPOLBL3MBTL1ATM | |
| SCHEMBL17293323 | 0.90 | TSHR (0.41) | KMT2ALMNAPOLBCYP2C19L3MBTL1 | |
| SCHEMBL17293536 | 0.84 | ALDH1A1 (0.44) | KMT2ALMNACYP2C19L3MBTL1ALDH1A1 | |
| SCHEMBL13774876 | 0.83 | USP2 (0.43) | KMT2ALMNACXCR2PKMCYP2C19 | |
| SCHEMBL9978081 | 0.83 | SPR (0.35) | KMT2ALMNACYP2C19ATMALDH1A1 | |
| SCHEMBL9977972 | 0.82 | LMNA (0.46) | KMT2ALMNAPOLBALDH1A1MEN1 | |
| SCHEMBL17293478 | 0.81 | MAPT (0.33) | KMT2ALMNAPOLBPKMATM | |
| SCHEMBL17293383 | 0.81 | HSD11B1 (0.42) | KMT2ALMNAATMALDH1A1MEN1 | |
| SCHEMBL3041529 | 0.81 | NAMPT (0.40) | KMT2ALMNAL3MBTL1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351933-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060084641-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-04-20 | — | — | US | disclosed |
| EP-1351933-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040048897-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
| EP-1351933-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002057230-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048897-A1 | Il-8 receptor antagonists | CXCL8, CCR8, TLR8 | RAB9A 1229/4885KMT2A 2291/4885LMNA 4799/4885 |
| US-20060084641-A1 | IL-8 receptor antagonists | CXCL8, CCR8, TLR8 | RAB9A 1229/4885KMT2A 2291/4885LMNA 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.